# Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

> **NCT00408967** · PHASE2 · WITHDRAWN · sponsor: **EMD Serono**

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Tucotuzumab celmoleukin (EMD 273066)

## Key facts

- **NCT ID:** NCT00408967
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-12-31
- **Primary completion:** 2008-05-31
- **Final completion:** 2008-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Th trial got cancelled and no subjects signed informed consent form (ICF); study design not appropriate any longer.
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408967, "Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00408967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*